Yahoo
Stockholm - Free Realtime Quote SEK

Devyser Diagnostics AB (publ) (DVYSR.ST)

64.90 +3.40 (+5.53%)
As of 4:47:04 PM GMT+1. Market Open.
DVYSR.ST Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for DVYSR.ST
  • Previous Close 61.50
  • Open 65.10
  • Bid 64.20 x --
  • Ask 64.70 x --
  • Day's Range 62.00 - 68.00
  • 52 Week Range 48.50 - 124.00
  • Volume 70,518
  • Avg. Volume 17,507
  • Market Cap (intraday) 1.096B
  • Beta (5Y Monthly) 0.80
  • PE Ratio (TTM) 70.54
  • EPS (TTM) 0.92
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 96.12

Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.

devyser.com

110

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

DVYSR.ST
43.17%
OMX Stockholm 30 Index (^OMX)
14.00%

1-Year Return

DVYSR.ST
47.24%
OMX Stockholm 30 Index (^OMX)
19.28%

3-Year Return

DVYSR.ST
6.74%
OMX Stockholm 30 Index (^OMX)
54.54%

5-Year Return

DVYSR.ST
27.89%
OMX Stockholm 30 Index (^OMX)
41.81%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 59.7M
Earnings 7.3M
Profit Margin 12.23%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
20M
40M
60M
5.0%
10.0%
15.0%

Analyst Insights

View More

Analyst Price Targets

88.24
96.12 Average
64.90 Current
104.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.15%

  • Return on Assets (ttm)

    3.14%

  • Return on Equity (ttm)

    4.28%

  • Revenue (ttm)

    250.3M

  • Net Income Avi to Common (ttm)

    15.4M

  • Diluted EPS (ttm)

    0.92

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    81M

  • Total Debt/Equity (mrq)

    12.02%

  • Levered Free Cash Flow (ttm)

    -27.3M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: